Dr. Albert DeNittis, MD
Claim this profileLankenau Medical Center
Expert in Cancer
Expert in Lung Cancer
59 reported clinical trials
120 drugs studied
About Albert DeNittis, MD
Education:
- Received MD from Sidney Kimmel Medical College (formerly Jefferson Medical College) in 1986.
- Completed Residency in Internal Medicine at Lankenau Medical Center in 1989.
- Finished Fellowship in Hematology/Oncology at Fox Chase Cancer Center in 1992.
Experience:
- Affiliated with Lankenau Medical Center and Main Line Health.
- Practices as a hematologist and oncologist.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Albert DeNittis, MD is currently running
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Albert DeNittis, MD
Clinical Trial Related4 years of experience running clinical trials · Led 59 trials as a Principal Investigator · 31 Active Clinical TrialsTreatments Albert DeNittis, MD has experience with
- Paclitaxel
- Carboplatin
- Pembrolizumab
- Atezolizumab
- Olaparib
- Docetaxel
Breakdown of trials Albert DeNittis, MD has run
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Albert DeNittis, MD specialize in?
Albert DeNittis, MD focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Albert DeNittis, MD currently recruiting for clinical trials?
Yes, Albert DeNittis, MD is currently recruiting for 31 clinical trials in Wynnewood Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Albert DeNittis, MD has studied deeply?
Yes, Albert DeNittis, MD has studied treatments such as Paclitaxel, Carboplatin, Pembrolizumab.
What is the best way to schedule an appointment with Albert DeNittis, MD?
Apply for one of the trials that Albert DeNittis, MD is conducting.
What is the office address of Albert DeNittis, MD?
The office of Albert DeNittis, MD is located at: Lankenau Medical Center, Wynnewood, Pennsylvania 19096 United States. This is the address for their practice at the Lankenau Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.